Prostate Cancer - Results from #20920

Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk - Abstract March 25, 2014

The use of androgen deprivation therapy (ADT) and chemotherapeutic agents in New Zealand men with prostate cancer - Abstract March 25, 2014

An update on occupation and prostate cancer - Abstract March 25, 2014

Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer - Abstract March 25, 2014

Radiation safety considerations for the use of (223)RaCl(2) DE in men with castration-resistant prostate cancer - Abstract March 25, 2014

Salvage therapy for castration-refractory prostate cancer resistant to docetaxel - Abstract March 25, 2014

Diffusion-weighted MRI as a predictor of extracapsular extension in prostate cancer - Abstract March 24, 2014

The Postoperative Morbidity Index: A quantitative weighing of postoperative complications applied to urological procedures - Abstract March 24, 2014

NICE unable to give the go ahead to new prostate cancer drug in preliminary recommendations March 24, 2014

A modelled comparison of prostate cancer control rates after high-dose-rate brachytherapy (3145 multicentre patients) combined with, or in contrast to, external-beam radiotherapy - Abstract March 24, 2014

A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer - Abstract March 24, 2014

A comparison of two methods for estimating DCE-MRI parameters via individual and cohort based AIFs in prostate cancer: A step towards practical implementation - Abstract March 24, 2014

The Quadrella: A novel approach to analyzing optimal outcomes after permanent seed prostate brachytherapy - Abstract March 24, 2014

The impact of rectal and bladder variability on target coverage during post-prostatectomy intensity modulated radiotherapy - Abstract March 24, 2014

Does family history of prostate cancer affect outcomes following radiotherapy? - Abstract March 24, 2014

Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases - Abstract March 24, 2014

Maintaining and reprogramming genomic androgen receptor activity in prostate cancer - Abstract March 24, 2014

Role of PSA-related variables in improving positive ratio of biopsy of prostate cancer within serum PSA gray zone - Abstract March 21, 2014

A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer - Abstract March 21, 2014

Sector analysis of dosimetry of prostate cancer patients treated with low-dose-rate brachytherapy - Abstract March 21, 2014

Page 1047 of 1435